GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$150.11
−0.52%Jul 6, 2026, 19:41 UTC
Gilead Sciences received FDA approval to expand the label of Trodelvy for first-line metastatic triple-negative breast cancer.
Source:Jun 25, 2026, 10:45 UTC
The U.S. FDA approved Merck's KEYTRUDA and KEYTRUDA QLEX, each in combination with Gilead's Trodelvy, for first-line treatment of PD-L1+ advanced triple-negative breast cancer.
Source:Jun 24, 2026, 16:25 UTC
Gilead Sciences received European Commission approval to expand Trodelvy's label to include first-line treatment of metastatic triple-negative breast cancer.
Source:Jun 23, 2026, 11:45 UTC
The European Commission granted marketing authorization for Gilead Sciences' Trodelvy as a first-line treatment for metastatic triple-negative breast cancer patients not candidates for PD-(L)1 inhibitors.
Source:Jun 15, 2026, 19:46 UTC
The U.S. Food and Drug Administration approved Gilead Sciences' experimental drug Hepcludex for the treatment of chronic hepatitis delta virus.
Source:Jun 9, 2026, 20:36 UTC
Gilead and Merck end a lung cancer study.
Source:Jun 8, 2026, 20:30 UTC
Merck and Gilead discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 study based on an external Data Monitoring Committee recommendation.
Source:Jun 4, 2026, 20:59 UTC
Gilead Sciences and Lakefront Capital completed the acquisition of Ouro Medicines.
Jun 3, 2026, 16:21 UTC
Gilead Sciences reported positive phase III IDEAL study results for Livdelzi in primary biliary cholangitis patients, showing improved ALP normalization.
Source:
← PreviousPage 2